Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Illumina Inc ILMN

Technology Scientific & Technical Instruments
Illumina, Inc. is a provider of sequencing and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.


NDAQ:ILMN - Post by User

Illumina Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(161)
•••
Post by R_J_on Nov 01, 2020 9:47am
298 Views
Post# 31819927

End of Month - October 2020

End of Month - October 2020End of the Month Report for October 2020 for Illumina Inc.
-
ILMN closed on 10/30/2020 at US$ 292.7
ILMN closed on 09/30/2020 at US$ 309.08
ILMN closed on 08/31/2020 at US$ 357.22
ILMN closed on 07/31/2020 at US$ 382.16
-
This is a   5.3% loss, a US$ 16.38 loss, for October
This is a 22.4% loss, a US$ 89.49 loss, for August, September & October, altogether.
-
S&P 500 Index, @ 3269.9 lost 2.8% in October. [4.5% above its MA(200) @ 3129.4]
-
Two Hundred Day Moving Average [MA(200)] stuff.
ILMN's  MA(200) ended October at US$324.16
ILMN is now 9.7% below its MA(200).
-
News Release on the ILMN Website in October
-
Oct 29, 2020     
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2020
-
https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=93d9108f-be6d-4b1a-b79f-31b2f8ee2dfa
-
Who is in charge?
Francis A. DeSouza, CEO
-
RJ
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities